23 June 2022
Navitas Life Sciences, a provider of Pharmacovigilance, Regulatory, and Clinical solutions, today announced that it has been named as a ‘Major Contender’ in the Everest Group’s Life Sciences Operations PEAK Matrix® Assessment 2022.
The PEAK Matrix® assessment provides the analysis and insights that enterprises need to make critical selection decisions about service providers, locations, and products and solutions. For this research report, Navitas Life Sciences is one of 32 global service providers to feature. The report provides a detailed analysis and includes the relative positioning of providers for Life Sciences Operations Services, a comparison of the providers’ capabilities and market shares, as well as an analysis of providers’ strengths and limitations.
The report recognizes that in the midst of the COVID-19 pandemic, the life sciences industry has undergone several changes, not least an omnichannel approach as well as the decentralized approach to clinical trials. In addition, there is an increased focus on pharmacovigilance and patient safety.
At Navitas Life Sciences we are proud to be driving better outcomes for drug development. Motivated by the success of our clients, we work to accelerate access to better healthcare for people across the world with our end-to-end services and solutions for life sciences.
For further information, or to read the Everest Group’s Life Sciences Operations PEAK Matrix® Assessment 2022 please visit: https://www2.everestgrp.com/reportaction/EGR-2022-54-R-5236/Marketing